-
-
-
-
-
-
-
Truist SecuritiesReinstates $25 target on Harmony Biosciences Holdings Inc. (HRMY)
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
-
-
-
-
-
-
-
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Tops Q2 EPS by $1.05, provides guidance
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Tops Q4 EPS by 1c
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
-
1,208,459 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

